<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05797987</url>
  </required_header>
  <id_info>
    <org_study_id>YOUNGBC-25</org_study_id>
    <nct_id>NCT05797987</nct_id>
  </id_info>
  <brief_title>Negative ER Expression Assessed by 18F-FES PET/CT in the MBC With ER-positive Primary Tumor</brief_title>
  <official_title>Negative Estrogen Receptor (ER) Expression Assessed by 18F-fluoroestradiol Positron Emission Tomography/Computed Tomography (18F-FES PET/CT) in the Metastatic Breast Cancer (MBC) With ER-positive Primary Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the treatment pattern and efficacy of patients with positive primary ER lesion&#xD;
      but negative ER expression in MBC using a novel convenient way of 18F-fluoroestradiol&#xD;
      positron emission tomography/computed tomography (18F-FES PET/CT).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2022</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>6 weeks</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v 5.0</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>FES negative in MBC</arm_group_label>
    <description>Patients who did not present with any ER-positive lesions were characterized as with negative ER expression in the metastatic stage</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        MBC patients with ER-positive primary tumor who detected negative ER expression in&#xD;
        metastatic disease using 18F-FES PET/CT at the Fudan University Shanghai Cancer Center&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with breast cancer (according to International Classification of&#xD;
             Diseases 10th Revision) with confirmed metastasis, regardless of being de novo&#xD;
             diagnosed or progressed from a non-metastatic stage.&#xD;
&#xD;
          -  MBC patients who underwent 18F-FES PET/CT at the Fudan University Shanghai Cancer&#xD;
             Center between 2010 and 2022&#xD;
&#xD;
          -  Patients diagnosed with primary ER-positive tumor and who were yet to receive any&#xD;
             systemic therapy during the advanced stage&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with incomplete medical records and those diagnosed with secondary primary&#xD;
             tumors&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Biyun Wang</last_name>
    <phone>18017312387</phone>
    <email>pro_wangbiyun@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Biyun Wang, MD</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Biyun Wang</last_name>
      <phone>18017312387</phone>
      <email>pro_wangbiyun@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>March 22, 2023</study_first_submitted>
  <study_first_submitted_qc>March 22, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2023</study_first_posted>
  <last_update_submitted>April 5, 2023</last_update_submitted>
  <last_update_submitted_qc>April 5, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Biyun Wang, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

